We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
Read MoreHide Full Article
For Immediate Release
Chicago, IL –July 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Netflix (NFLX - Free Report) , Eli Lilly (LLY - Free Report) , BNY Mellon (BK - Free Report) , TJX Companies (TJX - Free Report) and Raytheon .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Netflix, Lilly and BNY Mellon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Eli Lilly and BNY Mellon. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Netflix’s shares have increased +97.6% year to date, significantly outperforming the Zacks Broadcast Radio and Television industry’s gain of +33.5% during the same period. Netflix’s second-quarter 2018 subscriber addition rate was disappointing.
Although management cited over-optimistic guidance, the Zacks analyst thinks the pace of subscriber additions has hit a rough patch due to increasing competition. Nevertheless, Netflix’s focus on providing quality content, expanding original movie slate, strong regional content portfolio and aggressive spending is expected to help it steer away competition.
Moreover, partnerships with telcos like Telefonica in Spain and Latin America as well as KDDI in Japan are expected to boost subscriber addition. However, the company’s increasing marketing spends and higher investments on content will hurt profitability, unless subscriber addition rebounds. Further, strengthening U.S. dollar doesn’t bode well for operating margin expansion. Cash burn is also expected to continue in the near term.
Shares of Buy-ranked Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry year to date (+6.1% vs. -0.7%). Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year.
The Zacks analyst thinks the decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent decision. However, competitive pressure on Lilly’s drugs is expected to rise this year. Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron.
U.S. pricing access pressure will also remain a headwind in 2018. Estimates have gone up slightly ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters.
BNY Mellon’s shares have outperformed the Zacks Major Regional Banks industry in the last six months (-4.6% vs. -7.2%). Also, the company has an impressive earnings surprise history, having surpassed expectations in three of the trailing four quarters. The Zacks analyst thinks higher interest rates, loan growth and improving fee income will aid revenue growth.
Lesser regulations, tax cuts and cost-saving initiatives are likely to continue driving profitability. Further, enhanced capital deployment plan reflects a strong balance sheet. However, concentration risk arising from significant dependence on fee-based income remains a matter of concern.
If there is any change in individual investment preferences, regulatory amendments or a slowdown in capital market activities, it might hamper the company's financials. Also, earnings estimate has moved lower ahead of the company's second quarter results.
Other noteworthy reports we are featuring today include TJX Companies and Raytheon.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
For Immediate Release
Chicago, IL –July 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Netflix (NFLX - Free Report) , Eli Lilly (LLY - Free Report) , BNY Mellon (BK - Free Report) , TJX Companies (TJX - Free Report) and Raytheon .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Netflix, Lilly and BNY Mellon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Eli Lilly and BNY Mellon. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Netflix’s shares have increased +97.6% year to date, significantly outperforming the Zacks Broadcast Radio and Television industry’s gain of +33.5% during the same period. Netflix’s second-quarter 2018 subscriber addition rate was disappointing.
Although management cited over-optimistic guidance, the Zacks analyst thinks the pace of subscriber additions has hit a rough patch due to increasing competition. Nevertheless, Netflix’s focus on providing quality content, expanding original movie slate, strong regional content portfolio and aggressive spending is expected to help it steer away competition.
Moreover, partnerships with telcos like Telefonica in Spain and Latin America as well as KDDI in Japan are expected to boost subscriber addition. However, the company’s increasing marketing spends and higher investments on content will hurt profitability, unless subscriber addition rebounds. Further, strengthening U.S. dollar doesn’t bode well for operating margin expansion. Cash burn is also expected to continue in the near term.
Shares of Buy-ranked Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry year to date (+6.1% vs. -0.7%). Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year.
The Zacks analyst thinks the decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent decision. However, competitive pressure on Lilly’s drugs is expected to rise this year. Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron.
U.S. pricing access pressure will also remain a headwind in 2018. Estimates have gone up slightly ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters.
BNY Mellon’s shares have outperformed the Zacks Major Regional Banks industry in the last six months (-4.6% vs. -7.2%). Also, the company has an impressive earnings surprise history, having surpassed expectations in three of the trailing four quarters. The Zacks analyst thinks higher interest rates, loan growth and improving fee income will aid revenue growth.
Lesser regulations, tax cuts and cost-saving initiatives are likely to continue driving profitability. Further, enhanced capital deployment plan reflects a strong balance sheet. However, concentration risk arising from significant dependence on fee-based income remains a matter of concern.
If there is any change in individual investment preferences, regulatory amendments or a slowdown in capital market activities, it might hamper the company's financials. Also, earnings estimate has moved lower ahead of the company's second quarter results.
Other noteworthy reports we are featuring today include TJX Companies and Raytheon.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.